RMC-4630

About REVOLUTION Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company with a mission to develop targeted therapies for RAS-addicted cancers, one of the most prevalent and challenging oncogenic drivers. Its core achievement is the development of a proprietary tri-complex inhibitor platform that enables the direct targeting of active, GTP-bound 'RAS(ON)' proteins, a frontier long considered undruggable. The company's strategy is to advance a deep pipeline of RAS(ON) inhibitors through clinical development, aiming to establish a new standard of care. This scientific and strategic focus has garnered significant investor confidence, reflected in its substantial market valuation.

Therapeutic Areas